First, the genomic heterogeneity of GBM is crucial in determining the efficacy of immunotherapies, since specific mutations such as PTEN, MAPK pathway alterations, germline DNA polymerase epsilon and broad mutation, such as somatic mutations, microsatellite instability and tumor mutational burden, seem to acquire prognostic and predictive values [158]. The gene discussed is PTEN; the disease is neoplasm.